Source: Eur Respir J, 50 (1) 1700648; 10.1183/13993003.00648-2017
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Jose A. Caminero, Alberto Piubello, Anna Scardigli, Giovanni Battista Migliori. Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases. Eur Respir J, 50 (1) 1700648; 10.1183/13993003.00648-2017

Member's Comments

No comment yet.

Related content which might interest you: The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens Source: Eur Respir J, 50 (5) 1701105; 10.1183/13993003.01105-2017 Year: 2017 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen Source: Eur Respir J, 52 (6) 1801528; 10.1183/13993003.01528-2018 Year: 2018 Efficacy of linezolide-free chemotherapy schemes in patients with highly drug-resistant tuberculosis Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021 Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001 The effectiveness of the introduction of the updated treatment regimens and microbiological diagnostics MDR/XDR tuberculosis Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 The individual-tailored treatment regimens for multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Treatment options for patients with multidrug-resistant or extensively drug-resistant tuberculosis Source: Annual Congress 2009 - Priorities in tuberculosis research Year: 2009 Is standardized treatment appropriate for non-XDR multiple drug resistant TB? Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Comparison of compliance of two therapeutic regimens in treatment of latent tuberculosis infection in Belgrade children Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004 Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases Source: Eur Respir J 2008; 31: 1155-1159 Year: 2008 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Source: Eur Respir J 2009; 33: 1085-1094 Year: 2009 All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings Source: Eur Respir J, 59 (1) 2004345; 10.1183/13993003.04345-2020 Year: 2022 The continued hunt for the elusive standard short regimen for treatment of multidrug-resistant tuberculosis Source: Eur Respir J, 55 (3) 2000224; 10.1183/13993003.00224-2020 Year: 2020 WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Source: Eur Respir J 2011; 38: 516-528 Year: 2011